{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:07:50Z","timestamp":1762445270830,"version":"3.41.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Vaccination against coronavirus disease 2019 (COVID-19) is currently under worldwide deployment. The consequences of this vaccination can be seen in radiology and nuclear medicine explorations with visualization of axillary lymph nodes (LNs), as observed on ultrasonography, MRI, or <jats:sup>18<\/jats:sup>F-FDG PET\/CT.<\/jats:p>\n            <jats:p>We aimed to evaluate on PET\/CT the incidence of vaccine-related LNs and their characteristics after COVID-19 vaccination, using several radiopharmaceuticals different from <jats:sup>18<\/jats:sup>F-FDG.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Between February and July 2021, all consecutive patients undergoing a whole-body PET\/CT for any indication using a different radiopharmaceutical from <jats:sup>18<\/jats:sup>F-FDG were eligible for inclusion if they had received at least 1 dose of the COVID-19 vaccine. The radiopharmaceutical administered and vaccine type were recorded for each patient. The incidence of positive vaccine-related axillary and supraclavicular LNs on PET\/CT was our primary finding, along with the nodes characteristics. Statistical analyses were performed for patients with prostate cancer (PCa) to determine certain interaction factors that were associated with the detection of vaccine-related LNs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 226 patients in our cohort study, 120 patients underwent an <jats:sup>18<\/jats:sup>F-fluorocholine PET\/CT, 79 a <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT, 6 an <jats:sup>18<\/jats:sup>F-FDOPA PET\/CT, and 21 a <jats:sup>68<\/jats:sup>Ga-DOTATOC PET\/CT. A total of 67.3% of patients (152\/226) received BNT162b2mRNA (Pfizer-BioNTech), 26.5% (60\/226) ChAdOx1-S (AstraZeneca), 4.9% (11\/226) mRNA-1273 (Moderna), and 1.3% (3\/226) Ad26.COV2.S (Janssen). The incidence of positive vaccine-related axillary and supraclavicular LNs was 42.5% (51\/120 patients) on PET\/CT using <jats:sup>18<\/jats:sup>F-fluorocholine and 12.7% (10\/79 patients) with <jats:sup>68<\/jats:sup>Ga-PSMA-11. None of our patients undergoing <jats:sup>18<\/jats:sup>F-FDOPA or <jats:sup>68<\/jats:sup>Ga-DOTATOC PET\/CT presented any vaccine-related lymphadenopathy. Vaccine-related LNs were statistically associated with the nature of the radiopharmaceutical (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 10<jats:sup>\u22124<\/jats:sup>), with the number of vaccine doses received (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.041), with a short delay between vaccination and PET\/CT realization (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 10<jats:sup>\u22125<\/jats:sup>), and with a higher prostate-specific antigen level for patients with PCa (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.032), but not with age or vaccine type. The vaccine-related nodes appeared in 85% of the cases, in the 30 days after vaccine injection, were limited in size and uptake, and were most often limited to the axilla level 1 area.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Detecting positive LNs after COVID-19 vaccination is not an exclusive <jats:sup>18<\/jats:sup>F-FDG PET\/CT pattern but is common on <jats:sup>18<\/jats:sup>F-fluorocholine and possible on <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT. Confronting PET\/CT findings with clinical data (such as date and site of injection) seems essential in the current pandemic context, just as it does for the radiopharmaceuticals used in PCa to avoid PET\/CT misinterpretation and incorrect patient treatment. For <jats:sup>18<\/jats:sup>F-FDOPA or <jats:sup>68<\/jats:sup>Ga-DOTATOC PET\/CT, this seems to have a lesser impact.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004190","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T14:13:09Z","timestamp":1649167989000},"page":"575-582","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Vaccine-Related Lymph Nodes"],"prefix":"10.1097","volume":"47","author":[{"given":"Loic","family":"Ah-Thiane","sequence":"first","affiliation":[{"name":"ICO Ren\u00e9 Gauducheau, Saint-Herblain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovic","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Maucherat","sequence":"additional","affiliation":[{"name":"ICO Ren\u00e9 Gauducheau, Saint-Herblain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Fleury","sequence":"additional","affiliation":[{"name":"ICO Ren\u00e9 Gauducheau, Saint-Herblain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maelle","family":"Le Thiec","sequence":"additional","affiliation":[{"name":"ICO Ren\u00e9 Gauducheau, Saint-Herblain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Rusu","sequence":"additional","affiliation":[{"name":"ICO Ren\u00e9 Gauducheau, Saint-Herblain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","article-title":"A global database of COVID-19 vaccinations","volume":"5","year":"2021","journal-title":"Nat Hum Behav"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","year":"2020","journal-title":"N Engl J Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.clinimag.2021.01.016","article-title":"Unilateral axillary adenopathy in the setting of COVID-19 vaccine","volume":"75","year":"2021","journal-title":"Clin Imaging"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2214\/AJR.21.25604","article-title":"Management of unilateral axillary lymphadenopathy detected on breast MRI in the era of COVID-19 vaccination","volume":"217","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"E323","DOI":"10.1148\/radiol.2021210436","article-title":"Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: radiology scientific expert panel","volume":"300","year":"2021","journal-title":"Radiology"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"e210008","DOI":"10.1148\/ryct.2021210008","article-title":"Axillary lymphadenopathy after mRNA COVID-19 vaccination","volume":"3","year":"2021","journal-title":"Radiol Cardiothorac Imaging"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"E296","DOI":"10.1148\/radiol.2021210275","article-title":"Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncologic patients","volume":"300","year":"2021","journal-title":"Radiology"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1007\/s00259-021-05278-3","article-title":"COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET\/CT in a patient affected by melanoma","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2214\/AJR.21.25728","article-title":"COVID-19 vaccination-related uptake on FDG PET\/CT: an emerging dilemma and suggestions for management","volume":"217","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/RLU.0000000000001603","article-title":"Lymph node activation by PET\/CT following vaccination with licensed vaccines for human papillomaviruses","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/RLU.0b013e3182177322","article-title":"Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine","volume":"36","year":"2011","journal-title":"Clin Nucl Med"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1007\/s00259-021-05279-2","article-title":"Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]choline PET\/CT\u2014not only an FDG finding","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/1097-0142(1955)8:4<776::AID-CNCR2820080421>3.0.CO;2-B","article-title":"The significance of axillary node levels in the study of breast carcinoma","volume":"8","year":"1955","journal-title":"Cancer"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00259-021-05314-2","article-title":"Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2967\/jnumed.121.262194","article-title":"Covid-19 mRNA vaccination: age and immune status and its association with axillary lymph node PET\/CT uptake","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1016\/j.vaccine.2011.04.077","article-title":"Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults","volume":"29","year":"2011","journal-title":"Vaccine"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.exger.2017.10.024","article-title":"Age and immunity: what is \u201cimmunosenescence\u201d?","volume":"105","year":"2018","journal-title":"Exp Gerontol"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ageing\/afaa274","article-title":"Efficacy and safety of COVID-19 vaccines in older people","volume":"50","year":"2021","journal-title":"Age Ageing"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"101205","DOI":"10.1016\/j.arr.2020.101205","article-title":"Aging in COVID-19: vulnerability, immunity and intervention","volume":"65","year":"2021","journal-title":"Ageing Res Rev"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s00259-021-05331-1","article-title":"Medical imaging in times of pandemic: focus on the cornerstones of successful imaging","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1177\/0300060518773019","article-title":"PET\/CT analysis of 21 patients with breast cancer: physiological distribution of 18F-choline and diagnostic pitfalls","volume":"46","year":"2018","journal-title":"J Int Med Res"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.cpet.2014.03.001","article-title":"Fluorocholine PET\/computed tomography: physiologic uptake, benign findings, and pitfalls","volume":"9","year":"2014","journal-title":"PET Clin"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/RLU.0000000000000817","article-title":"Incidental detection of a Hodgkin lymphoma on 18F-choline PET\/CT and comparison with 18F-FDG in a patient with prostate cancer","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MNM.0b013e328330adc5","article-title":"18F-choline PET\/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer","volume":"31","year":"2010","journal-title":"Nucl Med Commun"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/RLU.0000000000000303","article-title":"(18)F-choline PET\/CT pitfalls in image interpretation: an update on 300 examined patients with prostate cancer","volume":"39","year":"2014","journal-title":"Clin Nucl Med"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.nucmedbio.2017.04.004","article-title":"PET\/CT with 18F-choline: physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients: 18F-choline PET\/CT bio-distribution and pitfalls. A southern Italian experience","volume":"51","year":"2017","journal-title":"Nucl Med Biol"},{"key":"bib33-20250621","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12967-017-1283-8","article-title":"Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies","volume":"15","year":"2017","journal-title":"J Transl Med"},{"key":"bib34-20250621","first-page":"20210040","article-title":"COVID-19 vaccine-related lymph node activation\u2014patterns of uptake on PET-CT","volume":"7","year":"2021","journal-title":"BJR Case Rep"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00259-003-1337-4","article-title":"18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET","volume":"31","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"11600","DOI":"10.1074\/jbc.RA118.003180","article-title":"Choline transport links macrophage phospholipid metabolism and inflammation","volume":"293","year":"2018","journal-title":"J Biol Chem"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40644-020-00300-7","article-title":"Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings","volume":"20","year":"2020","journal-title":"Cancer Imaging"},{"key":"bib38-20250621","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2967\/jnumed.117.203570","article-title":"Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/RLU.0000000000003723","article-title":"COVID-19 lung findings detected by 68Ga-PSMA PET\/CT for staging purposes in patients with prostate cancer","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib40-20250621","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/infdis\/jiab347","article-title":"Cell adhesion molecules and vascular endothelial growth factor at the systemic and alveolar level in coronavirus disease 2019 acute respiratory distress syndrome","volume":"224","year":"2021","journal-title":"J Infect Dis"},{"key":"bib41-20250621","first-page":"1663","article-title":"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna vaccines","volume":"25","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"bib42-20250621","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s00330-021-08122-2","article-title":"[18F]FDG uptake of axillary lymph nodes after COVID-19 vaccination in oncological PET\/CT: frequency, intensity, and potential clinical impact","volume":"32","year":"2022","journal-title":"Eur Radiol"},{"key":"bib43-20250621","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00259-011-1729-9","article-title":"Duration of 18F-FDG avidity in lymph nodes after pandemic H1N1v and seasonal influenza vaccination","volume":"38","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib44-20250621","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","article-title":"Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma","volume":"37","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib45-20250621","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/13814788.2021.1946681","article-title":"COVID-19\u2019s impact on primary care and related mitigation strategies: a scoping review","volume":"27","year":"2021","journal-title":"Eur J Gen Pract"},{"key":"bib46-20250621","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1080\/21505594.2021.1929800","article-title":"The journey of SARS-CoV-2 in human hosts: a review of immune responses, immunosuppression, and their consequences","volume":"12","year":"2021","journal-title":"Virulence"},{"key":"bib47-20250621","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against Covid-19 in Israel","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"bib48-20250621","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1148\/radiology.220.2.r01au25373","article-title":"Whole-body 18F Dopa PET for detection of gastrointestinal carcinoid tumors","volume":"220","year":"2001","journal-title":"Radiology"},{"key":"bib49-20250621","first-page":"9713691","article-title":"Prospective of 68Ga radionuclide contribution to the development of imaging agents for infection and inflammation","volume":"2018","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"key":"bib50-20250621","first-page":"174","article-title":"DOTATATE uptake in an axillary lymph node after COVID-19 vaccination","volume":"47","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib51-20250621","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/RLU.0000000000003757","article-title":"COVID lessons continue: postvaccination somatostatin receptor-positive axillary nodes on DOTATATE imaging","volume":"47","year":"2022","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:00:45Z","timestamp":1750536045000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004190"}},"subtitle":["The Emerging Pitfalls of 18F-Fluorocholine and 68Ga-PSMA-11 PET\/CT in the Era of COVID-19 Vaccination"],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004190","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2022,4,27]]}}}